3.1.1. Eosinophils

The impact of OmeGo and fevipiprant on lung and splenic eosinophilia was assessed at the end of the trial. Compared to cod liver oil, a significant 7% (*p* ≤ 0.05) and 10% (*p* ≤ 0.01) decrease in BAL eosinophils was seen with low- and high-dose OmeGo, respectively, and an 18% (*p* ≤ 0.001) decrease with fevipiprant (Figure 2). Splenic eosinophilia was significantly reduced by 16% and 17% (both *p* ≤ 0.05) with low- and high-dose OmeGo, respectively, and by 23% (*p* ≤ 0.01) with fevipiprant (Figure 3).

**Figure 2.** Eosinophil cell count in bronchoalveolar lavage (BAL) fluid of mice at study end, illustrating mean eosinophil count with cod liver oil (vehicle control), two doses of OmeGo, or fevipiprant. Cells were quantified with a hemocytometer. \*\* denotes *p* < 0.01, \* denotes *p* < 0.05.
